For information on career opportunities at BD, visit www.bd.com/careers
Location: United States, New Jersey, Franklin Lakes
Employees: 10001+
Phone: +1 201-847-6800
Total raised: $600K
Founded date: 1907
Investors 2
| Date | Name | Website |
| - | Gilde Heal... | gildehealt... |
| - | Irrus Inve... | irrusinves... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 05.10.2022 | - | $600K | - |
Mentions in press and media 11
| Date | Title | Description |
| 26.03.2025 | Photocure appoints Jane Healy as Vice President and General Manager EMEA | Photocure appoints Jane Healy as Vice President and General Manager EMEA Wed, Mar 26, 2025 08:00 CET Report this content Press Release – Oslo, Norway, March 26, 2025: Photocure ASA (OSE: PHO), the Bladder Cancer Company, today announced the... |
| 24.04.2017 | Term Sheet — Monday, April 24 | OPEN MIC It’s feedback time. Paid Content Securing the enterprise without boundaries From ExtraHop Joe writes: Expecting evidence of transparency before investing, either crowdfunding, angel or venture, would improve outcomes for investors.... |
| 03.12.2013 | C.R. Bard lands $46M Dept. of Defense contract extension | Medical device giant C.R. Bard (NYSE:BCR) landed a new $46.3 million contract with the U.S. Defense Dept., extending for a 2nd year a deal to provide the agency with medical supplies. The new contract was granted at the maximum possible val... |
| 04.11.2013 | Boston Scientific closes Bard EP acquisition | Follow MedCity News on Facebook and Twitter for more updates. Promoted This Patient Experience Checklist Is Your Key To Success in 2021 As healthcare systems strive to recover from losses due to the pandemic, patient acquisition and retenti... |
| 13.05.2013 | C.R. Bard closes federal cancer treatment beef for $51M | C.R. Bard (NYSE:BCR) said it closed a deal reached last year with federal prosecutors to settle a probe into its brachytherapy business with a $51 million payment. The U.S. Health & Human Services Dept. subpoenaed Murray Hills, N.J.-bas... |
| 25.04.2012 | Boston Scientific wins PMA for Epic stent | Boston Scientific (NYSE:BSX) won pre-market approval from the FDA for its Epic self-expanding iliac stent. The watchdog agency approved the device for treating de novo or restenotic symptomatic atherosclerotic lesions in the iliac arteries,... |
| 17.01.2012 | Boston Scientific touts 9-month results from Epic stent trial | Updated 4:45 p.m. with competing device information at the bottom Boston Scientific’s (NYSE:BSX) Epic stent system knocked its primary 9-month endpoints out of the park, according to data from the company’s Orion trial. The company beat its... |
| 21.12.2011 | C.R. Bard buys Lutonix’s drug-coated balloon catheter for PAD for $225M | “In our evaluations, Lutonix has the only third-generation, drug-coated balloon technology,” Bard’s Chairman and CEO Timothy Ring said in a statement. “They also have a significant lead with respect to a U.S. launch.” Moxy received the CE M... |
| 21.12.2011 | Bard nabs angioplasty balloon maker for $325 million | Acquisitions Roundup | C.R. Bard (NYSE:BCR) acquired Minneapolis-based angioplasty balloon maker Lutonix Inc. for $325 million. The merger, announced during Bard’s 2012 guidance update conference call, grants Lutonix $225 million up front with another $100 millio... |
| - | C.R. Bard buys Lutonix’s drug-coated balloon catheter for PAD for $225M | C.R. Bard Inc. will acquire the Maple Grove, Minnesota startup Lutonix Inc. for its novel drug-coated balloon catheter for treatment of peripheral artery disease. New Jersey-based medical device firm Bard announced Tuesday it would pay $225... |
Show more